EUVIMEDEUVIMED entdecken
Klinische StudieMultizentrische StudieOpen Access · CC BY 4.0

Cryocure-VT: the safety and effectiveness of ultra-low-temperature cryoablation of monomorphic ventricular tachycardia in patients with ischaemic and non-ischaemic cardiomyopathies

Atul Verma iD, Vidal Essebag iD, Petr Neuzil iD, Katia Dyrda iD, Jippe Balt iD, Borislav Dinov iD, Angeliki Darma iD, Arash Arya iD, Frederic Sacher iD, Vivek Y Reddy iD, Lucas Boersma iD, Ilya Grigorov und 1 weitere

Europace · 2024

DOI: 10.1093/europace/euae076 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Europace, 2024. Verfasst von Atul Verma und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, McGill University Health Centre, D13.173, 1650 Cedar Avenue, Montreal, QC H3G 1A4, Canada. Hauptthemen laut MEDLINE: Cardiomyopathies, Catheter Ablation, Cryosurgery, Tachycardia, Ventricular. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Adagio Medical Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The ultra-low-temperature cryoablation (ULTC) ablation system using −196°C N2 cryogen has been reported to create lesions with freeze duration–dependent depth titratable to over 10 mm with minimum attenuation by scar. Cryocure-VT (NCT04893317) was a first-in-human clinical trial evaluating the safety and efficacy of a novel, purpose-built ULTC catheter in endocardial ablation of scar-dependent ventricular tachycardias (VTs). Methods and results This prospective, multi-centre study enrolled patients referred for de novo or second ablations of recurrent monomorphic VT of both ischaemic and non-ischaemic aetiologies. Primary safety and efficacy endpoints of the study were freedom from device- or procedure-related major adverse events (MAEs) up to 30 days post-ablation, acute non-inducibility of clinical VTs at the end of the procedure, and freedom from sustained VT or implantable defibrillator intervention at 6 months. Ultra-low-temperature cryoablation was performed in 64 patients (age 67 ± 11 years, 78% ischaemic, ejection fraction = 35 ± 10%) at 9 centres. The primary acute effectiveness endpoint was achieved in 94% (51/54) of patients in whom post-ablation induction was attempted. There were no protocol-defined MAEs; four procedure-related serious adverse events resolved without clinical sequelae. At 6-month follow-up, 38 patients (60.3%) remained VT-free, and freedom from defibrillator shock was 81.0%, with no significant difference between ischaemic and non-ischaemic cohorts. In 47 patients with defibrillator for at least 6 months prior to the ablation, the VT burden was reduced from median of 4, inter-quartile range (IQR, 1–9) to 0, IQR (0–2).

Conclusion

In this first-in-human multi-centre experience, endocardial ULTC ablation of monomorphic VT appears safe and effective in patients with both ischaemic-cardiomyopathy and non-ischaemic-cardiomyopathy. Clinical Trial Registration NCT04893317.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiomyopathiesCatheter AblationCryosurgeryTachycardia, VentricularAgedHumansMiddle AgedCicatrixProspective StudiesTemperatureTreatment Outcome

Stichwörter der Autor:innen

AblationClinical trialCryoablationOutcomesUltra-lowVentricular tachycardia

Autor:innen und Institutionen

  • Division of Cardiology, McGill University Health Centre, D13.173, 1650 Cedar Avenue, Montreal, QC H3G 1A4, Canada.
  • Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic.
  • Department of Medicine, Montreal Heart Institute, Montreal, QC, Canada.
  • Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
  • Department of Electrophysiology, Leipzig Heart Center, Leipzig, Germany.
  • Department for Internal Medicine, University Hospital Halle, Halle, Germany.

ORCID-Profile: Atul Verma, Vidal Essebag, Petr Neuzil, Katia Dyrda, Jippe Balt, Borislav Dinov, Angeliki Darma, Arash Arya, Frederic Sacher, Vivek Y Reddy, Lucas Boersma, Tom De Potter

Förderung

  • Adagio Medical Inc

Zitieren

APA

Verma, A., Essebag, V., Neuzil, P., Dyrda, K., Balt, J., Dinov, B., Darma, A., Arya, A., Sacher, F., Reddy, V. Y., Boersma, L., Grigorov, I., & De Potter, T. (2024). Cryocure-VT: the safety and effectiveness of ultra-low-temperature cryoablation of monomorphic ventricular tachycardia in patients with ischaemic and non-ischaemic cardiomyopathies. Europace. https://doi.org/10.1093/europace/euae076

Vancouver

Verma A, Essebag V, Neuzil P, Dyrda K, Balt J, Dinov B, et al. Cryocure-VT: the safety and effectiveness of ultra-low-temperature cryoablation of monomorphic ventricular tachycardia in patients with ischaemic and non-ischaemic cardiomyopathies. Europace. 2024. doi:10.1093/europace/euae076

BibTeX
@article{Verma2024,
  author = {Verma, Atul and Essebag, Vidal and Neuzil, Petr and Dyrda, Katia and Balt, Jippe and Dinov, Borislav and Darma, Angeliki and Arya, Arash and Sacher, Frederic and Reddy, Vivek Y and Boersma, Lucas and Grigorov, Ilya and De Potter, Tom},
  title = {Cryocure-VT: the safety and effectiveness of ultra-low-temperature cryoablation of monomorphic ventricular tachycardia in patients with ischaemic and non-ischaemic cardiomyopathies},
  journal = {Europace},
  year = {2024},
  doi = {10.1093/europace/euae076}
}
Kostenlos starten →